Clinical Trial Update: Pacritinib With Aza for Upfront Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 trial is evaluating pacritinib in combination with azacitidine for upfront treatment of myelodysplastic syndromes; the study is currently n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome Unclassifiable
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Pacritinib (pacritinib)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Myelodysplastic Syndromes, MDS | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING